Cyclic di-nucleotide compounds as sting agonists

US10766919B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael D. Altman · Cambridge, US
• Brian M. Andresen · Sharon, US
• Wonsuk Chang · Princeton, US
• Matthew L. Childers · Medfield, US
• Jared N. Cumming · Garwood, US
• Andrew M. Haidle · Cambridge, US
• Timothy J. Henderson · Natick, US
• James P. Jewell · Jersey City, US
• Rui Liang · Plainsboro, US
• Jongwon Lim · Lexington, US
• Hong Liu · Seattle, US
• Min Lu · San Diego, US
• Alan B. Northrup · Reading, US
• Ryan D. Otte · Natick, US
• Tony Siu · Brookline, US
• Benjamin Wesley Trotter · Medfield, US
• Quang T. Truong · Morganville, US
• Shawn P. Walsh · Bound Brook, US
• Kake Zhao · Westfield, US

Key dates

• Filing date: Feb 1, 2018
• Grant date: Sep 8, 2020
• Expiry date: Feb 1, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/7084
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A class of polycyclic compounds of general formula (I), of general formula (I′), or of general formula (I″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.